- Home
- DLHC vs LCTX Comparison
DLHC vs LCTX Comparison
Compare DLHC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- LCTX
- Stock Information
- Founded
- DLHC 1969
- LCTX 1990
- Country
- DLHC United States
- LCTX United States
- Employees
- DLHC N/A
- LCTX N/A
- Industry
- DLHC Business Services
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DLHC Consumer Discretionary
- LCTX Health Care
- Exchange
- DLHC Nasdaq
- LCTX Nasdaq
- Market Cap
- DLHC 117.4M
- LCTX 110.2M
- IPO Year
- DLHC N/A
- LCTX N/A
- Fundamental
- Price
- DLHC $7.81
- LCTX $0.51
- Analyst Decision
- DLHC
- LCTX Strong Buy
- Analyst Count
- DLHC 0
- LCTX 4
- Target Price
- DLHC N/A
- LCTX $5.25
- AVG Volume (30 Days)
- DLHC 53.9K
- LCTX 2.3M
- Earning Date
- DLHC 01-29-2025
- LCTX 11-14-2024
- Dividend Yield
- DLHC N/A
- LCTX N/A
- EPS Growth
- DLHC 410.00
- LCTX N/A
- EPS
- DLHC 0.51
- LCTX N/A
- Revenue
- DLHC $395,937,000.00
- LCTX $8,719,000.00
- Revenue This Year
- DLHC N/A
- LCTX N/A
- Revenue Next Year
- DLHC N/A
- LCTX $123.52
- P/E Ratio
- DLHC $15.09
- LCTX N/A
- Revenue Growth
- DLHC 5.34
- LCTX N/A
- 52 Week Low
- DLHC $7.34
- LCTX $0.48
- 52 Week High
- DLHC $17.58
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- DLHC 44.81
- LCTX 36.82
- Support Level
- DLHC $7.58
- LCTX $0.48
- Resistance Level
- DLHC $7.79
- LCTX $0.57
- Average True Range (ATR)
- DLHC 0.35
- LCTX 0.04
- MACD
- DLHC 0.02
- LCTX 0.01
- Stochastic Oscillator
- DLHC 42.73
- LCTX 17.86
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. It is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, and telehealth systems.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.